Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
Altimmune (Nasdaq: ALT), a clinical-stage biopharmaceutical company, has announced it will release its second quarter 2024 financial results on August 8, 2024. The company will also provide a business update during a conference call scheduled for 8:30 am E.T. on the same day. Investors can access the webcast live on Altimmune's Investor Relations website. Those wishing to join the call can register to receive dial-in numbers and a unique PIN. A replay of the call will be available on the Investor Relations website for up to three months after the event.
Altimmune (Nasdaq: ALT), un'azienda biofarmaceutica in fase clinica, ha annunciato che rilascerà i suoi risultati finanziari del secondo trimestre 2024 il 8 agosto 2024. L'azienda fornirà anche un aggiornamento aziendale durante una conferenza telefonica programmata per le 8:30 am E.T. dello stesso giorno. Gli investitori possono accedere alla diretta streaming sul sito web delle Relazioni con gli Investitori di Altimmune. Coloro che desiderano partecipare alla chiamata possono registrarsi per ricevere i numeri di accesso e un PIN unico. Una registrazione della chiamata sarà disponibile sul sito delle Relazioni con gli Investitori per un massimo di tre mesi dopo l'evento.
Altimmune (Nasdaq: ALT), una empresa biofarmacéutica en etapa clínica, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el 8 de agosto de 2024. La empresa también proporcionará una actualización comercial durante una llamada programada para las 8:30 am E.T. del mismo día. Los inversores pueden acceder a la transmisión en vivo en el sitio web de Relaciones con Inversores de Altimmune. Aquellos que deseen unirse a la llamada pueden registrarse para recibir los números de acceso y un PIN único. Se estará disponible una repetición de la llamada en el sitio web de Relaciones con Inversores durante un período de hasta tres meses después del evento.
Altimmune(Nasdaq: ALT)는 임상 단계의 생명공학 회사로서 2024년 2분기 재무 결과를 2024년 8월 8일에 발표할 것이라고 발표했습니다. 회사는 같은 날 동부 표준시 오전 8시 30분에 예정된 컨퍼런스 콜에서 비즈니스 업데이트도 제공합니다. 투자자는 Altimmune의 투자자 관계 웹사이트에서 실시간 웨비나에 접근할 수 있습니다. 통화에 참여하고 싶으신 분들은 다이얼 인 번호와 고유 PIN 번호를 받을 수 있도록 등록할 수 있습니다. 통화의 재생은 이벤트 후 최대 3개월 동안 투자자 관계 웹사이트에서 이용할 수 있습니다.
Altimmune (Nasdaq: ALT), une entreprise biopharmaceutique en phase clinique, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le 8 août 2024. L'entreprise fournira également une mise à jour commerciale lors d'une conférence téléphonique prévue pour 8h30 E.T. le même jour. Les investisseurs peuvent accéder à la diffusion en direct sur le site Web des relations avec les investisseurs d'Altimmune. Ceux qui souhaitent participer à l'appel peuvent s'inscrire pour recevoir les numéros de connexion et un code PIN unique. Un enregistrement de l'appel sera disponible sur le site des relations avec les investisseurs pendant un maximum de trois mois après l'événement.
Altimmune (Nasdaq: ALT), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat angekündigt, dass es seine finanziellen Ergebnisse für das zweite Quartal 2024 am 8. August 2024 veröffentlichen wird. Das Unternehmen wird auch ein Geschäftsupdate während einer für 8:30 Uhr E.T. am gleichen Tag anberaumten Telefonkonferenz bereitstellen. Anleger können die Live-Webcast auf der Investor-Relations-Website von Altimmune abrufen. Interessierte, die an der Telefonkonferenz teilnehmen möchten, können sich registrieren, um die Einwahlnummern und eine eindeutige PIN zu erhalten. Eine Aufzeichnung der Konferenz wird auf der Investor-Relations-Website bis zu drei Monate nach der Veranstaltung verfügbar sein.
- None.
- None.
GAITHERSBURG, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 and will provide a business update.
Altimmune management will host a conference call at 8:30 am E.T. on August 8 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.
Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contacts:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
FAQ
When will Altimmune (ALT) report its Q2 2024 financial results?
What time is Altimmune's (ALT) Q2 2024 earnings call scheduled for?
How can investors access Altimmune's (ALT) Q2 2024 earnings call?
Will there be a replay available for Altimmune's (ALT) Q2 2024 earnings call?
